IMCIVREE Approved by FDA for Acquired Hypothalamic Obesity March 19, 2026 7:00 PM EDT Listen to webcast Supporting Materials IMCIVREE Approved by FDA for Acquired Hypothalamic Obesity Presentation 1.1 MB Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
